第三阶段非小细胞肺癌患者的治疗模式:使用德国癌症注册数据的基于人口的研究
Ahmed Bedir1, Sneha Mehrotra2, Jessica Gnüchtel3,4
1Department of Radiation Oncology, Health Services Research Group, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.
Journal of cancer research and clinical oncology
|August 30, 2023
概括
肺癌诊断和治疗方面的进展显著改善了德国第三阶段非小细胞肺癌 (NSCLC) 患者的生存率. 与早期相比,现代治疗时代的整体存活率 (OS) 显著增加.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 肺癌是全球癌症死亡的主要原因,通常与诊断延迟有关.
- 第三阶段非小细胞肺癌 (NSCLC) 是一个重大的临床挑战.
研究的目的:
- 为了评估治疗模式和总生存期 (OS) 在德国第三阶段NSCLC患者超过12年.
- 评估不断变化的诊断和治疗策略对患者结果的影响.
主要方法:
- 来自德国癌症登记处的14606名第三阶段NSCLC患者的回顾性分析 (2007-2018).
- 根据治疗可用性,患者被分为三个时代:低可用性时代 (LAE),过渡时代 (TE) 和现代时代 (ME).
- 卡普兰-梅尔曲线和考克斯比例危险模型用于确定生存差异和危险比率 (HR).
主要成果:
- 中位数OS从LAE的16个月增加到ME的22个月.
- 与LAE相比,在ME诊断和治疗的患者显示0.78 (95%CI:0.74-0.83) 的降低危险比率 (HR).
- 联合放射治疗和化疗证明了最显著的生存益处 (HR 0.73;95% CI:0.66-0.82).
结论:
- 诊断和治疗方面的进步对于改善肺癌患者的治疗结果至关重要.
- 需要进一步的研究来评估免疫治疗对NSCLC存活率的影响.
相关概念视频
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


